Showing 1 to 12 of 152 results
Moderna Defends UK Drug Pricing Amid Industry Criticism
Moderna opened a \£150 million vaccine facility in Oxfordshire, defending the UK's drug pricing system after criticism from other pharmaceutical companies who have paused investments due to pricing disputes with the government.
Moderna Defends UK Drug Pricing Amid Industry Criticism
Moderna opened a \£150 million vaccine facility in Oxfordshire, defending the UK's drug pricing system after criticism from other pharmaceutical companies who have paused investments due to pricing disputes with the government.
Progress
32% Bias Score
Trump's Misleading Claim of 1000% Prescription Drug Price Reduction
President Trump repeatedly claims his "most favored nation" policy will cut prescription drug prices by 1000% or more, a mathematically impossible assertion; this claim is factually inaccurate, as a 100% reduction would mean the price drops to zero.
Trump's Misleading Claim of 1000% Prescription Drug Price Reduction
President Trump repeatedly claims his "most favored nation" policy will cut prescription drug prices by 1000% or more, a mathematically impossible assertion; this claim is factually inaccurate, as a 100% reduction would mean the price drops to zero.
Progress
44% Bias Score
Pfizer Acquires Metsera for $4.9 Billion to Enter Obesity Drug Market
Pfizer, the US pharmaceutical giant, has acquired the biopharmaceutical company Metsera for $4.9 billion to enter the obesity drug market, gaining access to Metsera's pipeline of obesity and cardiometabolic therapies.
Pfizer Acquires Metsera for $4.9 Billion to Enter Obesity Drug Market
Pfizer, the US pharmaceutical giant, has acquired the biopharmaceutical company Metsera for $4.9 billion to enter the obesity drug market, gaining access to Metsera's pipeline of obesity and cardiometabolic therapies.
Progress
40% Bias Score
EU Drug Shortages Remain a Critical Risk
The European Court of Auditors reports persistent critical shortages of essential medicines in the EU, reaching record highs in 2023 and 2024, affecting 136 medicines between January 2022 and October 2024, impacting all drug types and posing risks to public health and strategic autonomy.
EU Drug Shortages Remain a Critical Risk
The European Court of Auditors reports persistent critical shortages of essential medicines in the EU, reaching record highs in 2023 and 2024, affecting 136 medicines between January 2022 and October 2024, impacting all drug types and posing risks to public health and strategic autonomy.
Progress
16% Bias Score
Dutch Oncologists Develop Pioneering Immunotherapy Treatments, but Face Industry Opposition
Dutch oncologists have developed new immunotherapy treatments that cure more cancer patients with fewer drugs, but pharmaceutical companies are delaying wider access due to financial concerns.
Dutch Oncologists Develop Pioneering Immunotherapy Treatments, but Face Industry Opposition
Dutch oncologists have developed new immunotherapy treatments that cure more cancer patients with fewer drugs, but pharmaceutical companies are delaying wider access due to financial concerns.
Progress
48% Bias Score
MSD Scraps £1bn UK Expansion Amidst Government Underinvestment
American pharmaceutical giant MSD is canceling its £1bn UK expansion, citing insufficient government investment in the life sciences sector and relocating its research to the US, resulting in over 100 UK job losses.
MSD Scraps £1bn UK Expansion Amidst Government Underinvestment
American pharmaceutical giant MSD is canceling its £1bn UK expansion, citing insufficient government investment in the life sciences sector and relocating its research to the US, resulting in over 100 UK job losses.
Progress
20% Bias Score
Novo Nordisk Job Cuts Slow Danish Economic Growth
Novo Nordisk, a pharmaceutical company crucial to Denmark's economy, announced 5,000 job cuts, impacting economic growth projections and causing uncertainty.
Novo Nordisk Job Cuts Slow Danish Economic Growth
Novo Nordisk, a pharmaceutical company crucial to Denmark's economy, announced 5,000 job cuts, impacting economic growth projections and causing uncertainty.
Progress
20% Bias Score
Pfizer to Acquire Metsera for $7.3 Billion
Pfizer is close to acquiring the weight-loss drug startup Metsera for $7.3 billion, marking Pfizer's first major acquisition in two years and a significant entry into the lucrative weight-loss drug market.
Pfizer to Acquire Metsera for $7.3 Billion
Pfizer is close to acquiring the weight-loss drug startup Metsera for $7.3 billion, marking Pfizer's first major acquisition in two years and a significant entry into the lucrative weight-loss drug market.
Progress
32% Bias Score
Pfizer to Acquire Metsera for $4.9 Billion to Enter Obesity Drug Market
Pfizer announced a $4.9 billion cash acquisition of Metsera, a biopharmaceutical firm with a pipeline of obesity and cardiometabolic disease treatments, to expand into the growing obesity drug market.
Pfizer to Acquire Metsera for $4.9 Billion to Enter Obesity Drug Market
Pfizer announced a $4.9 billion cash acquisition of Metsera, a biopharmaceutical firm with a pipeline of obesity and cardiometabolic disease treatments, to expand into the growing obesity drug market.
Progress
44% Bias Score
Trump to Drugmakers: Raise Prices Abroad to Lower US Costs
President Trump plans to pressure drug manufacturers to increase prices in other countries to offset price reductions in the US, potentially impacting global drug pricing and raising legal concerns.
Trump to Drugmakers: Raise Prices Abroad to Lower US Costs
President Trump plans to pressure drug manufacturers to increase prices in other countries to offset price reductions in the US, potentially impacting global drug pricing and raising legal concerns.
Progress
24% Bias Score
AstraZeneca Halts UK Investment, Exacerbating Life Sciences Crisis
AstraZeneca paused a planned £200 million Cambridge expansion and scrapped a £450 million vaccine facility investment, mirroring similar decisions by Merck and Sanofi, raising concerns about the UK's competitiveness in the life sciences sector.
AstraZeneca Halts UK Investment, Exacerbating Life Sciences Crisis
AstraZeneca paused a planned £200 million Cambridge expansion and scrapped a £450 million vaccine facility investment, mirroring similar decisions by Merck and Sanofi, raising concerns about the UK's competitiveness in the life sciences sector.
Progress
56% Bias Score
Health Canada vows to expedite biosimilar drug approvals to reduce costs
Health Canada is addressing a backlog in biosimilar drug approvals, aiming to accelerate the market entry of cheaper alternatives to costly biologic drugs, driven by a 400 percent surge in submissions since 2016 and a need to reduce costs for public drug plans.
Health Canada vows to expedite biosimilar drug approvals to reduce costs
Health Canada is addressing a backlog in biosimilar drug approvals, aiming to accelerate the market entry of cheaper alternatives to costly biologic drugs, driven by a 400 percent surge in submissions since 2016 and a need to reduce costs for public drug plans.
Progress
20% Bias Score
Showing 1 to 12 of 152 results